Disease burden of myasthenia gravis in relation to oral corticosteroid dose: an insurance claims database study in Japan
OCS dose target non-achievers carry a higher burden than achievers. Broader implementation of effective treatment strategies is required to reduce long-term use of higher-dose OCS and the associated burden.
Authors
- Akiyuki Uzawa (ORCID: https://orcid.org/0000-0001-9252-1863)
- Shingo Konno (ORCID: https://orcid.org/0000-0002-8731-0663)
- Kentaro Taki (ORCID: https://orcid.org/0000-0002-6019-3110)
- Makoto Samukawa (ORCID: https://orcid.org/0000-0003-3464-0754)
- Yohei Ohashi (ORCID: https://orcid.org/0000-0002-2288-130X)
- Hiroshi Todaka
- Céline Quelen
- Izumi Mishiro
- Renata Majewska
- Zuzanna Lukowicz
Institutions
- Toho University (JP)
- Chiba University (JP)
- Toho University Ohashi Medical Center (JP)
- UCB Pharma (Japan) (JP)
- Day Kimball Healthcare (US)
- Diagnostics for the Real World (United States) (US)
- Kindai University (JP)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3389/fneur.2025.1662173
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.39